Cocrystal Pharma, Inc. Common Stock
COCP Real Time Price USDRecent trades of COCP by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by COCP's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication Jul. 16, 2024
-
Patent Title: Combination therapy for treatment of hcv Sep. 12, 2023
-
Patent Title: Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication May. 25, 2021
-
Patent Title: Inhibitors of hepatitis c virus polymerase Mar. 16, 2021
-
Patent Title: Inhibitors of hepatitis c virus polymerase Nov. 05, 2019
-
Patent Title: Inhibitors of hepatitis c virus polymerase Oct. 01, 2019
-
Patent Title: Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer Jul. 03, 2018
-
Patent Title: Potent and selective inhibitors of hepatitis c virus Apr. 03, 2018
-
Patent Title: Potent and selective inhibitors of hepatitis c virus Mar. 27, 2018
-
Patent Title: Potent and selective inhibitors of hepatitis c virus Nov. 10, 2015
-
Patent Title: Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections Nov. 03, 2015
-
Patent Title: Hcv ns3 protease inhibitors May. 26, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of COCP in WallStreetBets Daily Discussion
Recent insights relating to COCP
Recent picks made for COCP stock on CNBC
ETFs with the largest estimated holdings in COCP
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view COCP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.